14-day Premium Trial Subscription Try For FreeGet Free

Range Low Price High Price Comment
30 days $14.26 $29.44 Friday, 8th Dec 2023 IMGN stock ended at $29.21. This is 0.545% less than the trading day before Thursday, 7th Dec 2023. During the day the stock fluctuated 0.634% from a day low at $29.20 to a day high of $29.39.
90 days $12.43 $29.44
52 weeks $3.61 $29.44

Historical ImmunoGen prices

Date Open High Low Close Volume
2023-12-08 $29.30 $29.39 $29.20 $29.21 13 496 602
2023-12-07 $29.26 $29.37 $29.19 $29.37 10 882 077
2023-12-06 $29.20 $29.44 $29.17 $29.34 7 616 685
2023-12-05 $29.15 $29.28 $29.11 $29.21 15 148 698
2023-12-04 $29.10 $29.28 $29.05 $29.22 13 739 142
2023-12-01 $29.25 $29.35 $28.94 $29.32 30 120 635
2023-11-30 $29.20 $29.44 $28.76 $29.35 67 430 538
2023-11-29 $16.07 $16.69 $15.88 $16.06 4 551 621
2023-11-28 $16.12 $16.21 $15.67 $15.98 4 456 345
2023-11-27 $16.16 $16.34 $15.84 $16.16 3 113 677
2023-11-24 $16.15 $16.49 $15.92 $16.06 2 132 205
2023-11-22 $15.28 $16.26 $15.14 $16.14 4 625 359
2023-11-21 $14.82 $15.44 $14.74 $15.21 3 274 764
2023-11-20 $15.66 $16.00 $14.77 $14.94 5 204 214
2023-11-17 $15.71 $16.42 $15.61 $16.11 7 418 310
2023-11-16 $15.48 $16.02 $15.35 $15.59 3 456 701
2023-11-15 $15.61 $16.03 $15.56 $15.64 4 850 234
2023-11-14 $15.46 $15.94 $15.18 $15.76 4 971 260
2023-11-13 $14.53 $14.80 $14.26 $14.74 2 578 688
2023-11-10 $14.76 $14.94 $14.26 $14.76 3 482 861
2023-11-09 $15.95 $15.95 $14.62 $14.74 5 163 692
2023-11-08 $15.92 $16.14 $15.56 $15.74 2 771 477
2023-11-07 $16.22 $16.73 $15.79 $15.98 4 880 370
2023-11-06 $15.96 $16.20 $14.88 $16.02 7 206 048
2023-11-03 $15.86 $16.38 $15.25 $16.29 8 849 607
Click to get the best stock tips daily for free!

About ImmunoGen

ImmunoGen ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and... IMGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT